Table 2.
Summary of potential cross-reactivity immunity to SARS-CoV-2 from selected pathogens.
| SARS-Peptide Hits(1) | B(2) | CD8 T(3) | CD4 T(4) | Vaccine (5) | |
|---|---|---|---|---|---|
| Mumps virus (MuV) | 2 | 1 | 0 | 0 | Y |
| Measles virus (MeV) | 0 | 0 | 0 | 0 | Y |
| Rubella Virus (RuV) | 0 | 0 | 0 | 0 | Y |
| Hepatitis B virus (HBV) | 1 | 1 | 0 | 0 | Y |
| Varicella Zoster Virus (VZV) | 4 | 1 | 2 | 0 | Y |
| Polio Virus (PoV) | 0 | 0 | 0 | 0 | Y |
| Papilloma Virus (PaV) | 2 | 1 | 1 | 1 | Y |
| Rotavirus A (RTVA) | 0 | 0 | 0 | 0 | Y |
| Influenza A virus (IAV) | 0 | 0 | 0 | 0 | Y |
| Influenza B virus (IBV) | 0 | 0 | 0 | 0 | Y |
| Herpes simplex virus 1 (HSV1) | 0 | 0 | 0 | 0 | N |
| Herpes simplex virus 2 (HSV2) | 2 | 1 | 0 | 0 | N |
| Epstein–Barr virus (EBV) | 9 | 3 | 2 | 1 | N |
| human cytomegalovirus (HCMV) | 1 | 0 | 0 | 0 | N |
| human rhinovirus A (HRVA) | 1 | 1 | 0 | 0 | N |
| human rhinovirus B (HRVB) | 0 | 0 | 0 | 0 | N |
| human rhinovirus C (HRVC) | 0 | 0 | 0 | 0 | N |
| Human Immunodeficiency 1 (HIV1) | 0 | 0 | 0 | 0 | N |
| Bacille Calmette-Guérin (BCG) | 120 | 41 | 21 | 11 | Y |
| Bordetella pertussis (Bpe) | 111 | 36 | 18 | 12 | Y |
| Corynebacterium diphtheriae (Cdi) | 83 | 33 | 14 | 5 | Y |
| Clostridium tetani (Cte) | 85 | 34 | 17 | 7 | Y |
| Haemophilus influenzae (Hin) | 53 | 16 | 6 | 5 | Y |
| Neisseria meningitides (Nme) | 60 | 23 | 9 | 3 | Y |
| Streptococcus pneumoniae (Spn) | 61 | 19 | 13 | 6 | Y |
1Number of peptides in the relevant pathogen with ≥8 residues and identity ≥80% with SARS-CoV-2. 2Peptide hits with B cell reactivity ≥0.4 (predicted as cross-reactive B cell epitopes). 3Peptides predicted as cross-reactive CD8 T cell epitopes. 4Peptides predicted as cross-reactive CD4 T cell epitopes. 5Whether these pathogens are subject to vaccinations. Whole dataset available in Supplementary Dataset 1.